Nomenclature	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=545	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=546	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=547	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=548	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=549	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=550	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=551
HGNC, UniProt	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6219, http://www.uniprot.org/uniprot/Q16322	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6231, http://www.uniprot.org/uniprot/Q14721	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6232, http://www.uniprot.org/uniprot/Q92953	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6233, http://www.uniprot.org/uniprot/P48547	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6234, http://www.uniprot.org/uniprot/Q96PR1	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6235, http://www.uniprot.org/uniprot/Q14003	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6236, http://www.uniprot.org/uniprot/Q03721
Associated subunits	Kv β1 and Kv β2	Kv5.1, Kv6.1‐6.4, Kv8.1‐8.2 and Kv9.1‐9.3	Kv5.1, Kv6.1‐6.4, Kv8.1‐8.2 and Kv9.1‐9.3	–	–	–	MiRP2 is an associated subunit for Kv3.4
Channel blockers	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416 (pIC50 2.8) [http://www.ncbi.nlm.nih.gov/pubmed/10836990?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343 (Pore blocker) (pIC50 2) [http://www.ncbi.nlm.nih.gov/pubmed/16478442?dopt=AbstractPlus] – Rat	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416 (pIC50 2.8) [http://www.ncbi.nlm.nih.gov/pubmed/9612272?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343 (pIC50 2.6) [http://www.ncbi.nlm.nih.gov/pubmed/9612272?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416 (pIC50 4.5) [http://www.ncbi.nlm.nih.gov/pubmed/7517498?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343 (pIC50 3.7) [http://www.ncbi.nlm.nih.gov/pubmed/7517498?dopt=AbstractPlus] – Mouse	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416 (pIC50 4.6) [http://www.ncbi.nlm.nih.gov/pubmed/11790809?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343 (pIC50 4.2) [http://www.ncbi.nlm.nih.gov/pubmed/11790809?dopt=AbstractPlus] – Rat	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343 (pIC50 3.9) [http://www.ncbi.nlm.nih.gov/pubmed/1381835?dopt=AbstractPlus] – Rat	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343 (pIC50 3.5) [http://www.ncbi.nlm.nih.gov/pubmed/1378392?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1840526?dopt=AbstractPlus] – Rat
Selective channel blockers	–	–	–	–	–	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2578 (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/9506974?dopt=AbstractPlus] – Rat
Functional Characteristics	KV	KV	–	KV	KV	KA	KA